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ABSTRACT 
Background: Malnutrition is common in patients undergoing gastric cancer 
resection, leading to weight loss, although little is known about how this impacts on 
health related quality of life (HRQL) This study aimed to explore the association 
between HRQL and weight loss in patients 2 years after curative gastric cancer 
resection. 
Methods: Consecutive patients undergoing curative gastric cancer resection and 
surviving at least 2 years without disease recurrence were recruited. Patients 
completed the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) and the specific module for gastric 
cancer (STO22) before and 2 years postoperatively and associations between 
HRQL scores and patients with and without ≥ 10% body weight loss (BWL) were 
examined.  
Results: A total of 76 patients were included, of whom 51 (67%) had BWL ≥ 10%. 
At 2 years postoperatively, BWL ≥ 10% was associated with deterioration of all 
functional aspects of quality of life, with persistent pain (21.6%), diarrhoea (13.7%) 
and nausea/vomiting (13.7%). By contrast, none of the patients with BWL < 10% 
experienced severe nausea/vomiting, pain or diarrhoea. 
Conclusions: More than two thirds of patients surviving 2 years after curative 
gastric cancer resection experienced > 10% BWL. These patients suffered from 
more disabling symptoms than those without this extent of weight loss which 
impaired HRQL. 
Key words: Gastric cancer; surgery; quality of life; weight loss  
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INTRODUCTION 
Surgical resection, either alone or in combination with perioperative 
chemotherapy or adjuvant chemotherapy, or chemoradiation is the main curative 
treatment for locally advanced gastric cancer (1–3). Malnutrition has been widely 
recognized in gastric cancer patients because of the disease itself or because of the 
surgical and oncological treatments (4,5). Gavazzi et al.(5) analysed the nutritional 
status at the beginning of gastric cancer treatment and reported a body weight loss 
(BWL) ≥ 10% of usual weight in 17% of patients, having a negative influence on 
health-related quality of life (HRQL). Several studies have defined HRQL as an 
important additional outcome measure in gastric cancer patients undergoing 
resection, showing differences between surgical techniques (6–8) as well as 
providing prognostic information (9–11). 
A greater than 10% baseline BWL has been considered as a severe 
nutritional risk indicator in patients with gastrointestinal cancer (12,13). Previous 
studies have found that patients undergoing total gastrectomy will lose 7%-15% of 
their body weight, usually within the first year of surgery, and will not return to a pre-
operative weight (14–16). The reduction in calorie intake as well as malabsorption 
are considered the main factors responsible for BWL(14). The extent of 
postoperative BWL seen postoperatively has been related to a deterioration of 
HRQL after oesophageal cancer resection (17).  
Little is known, however, about long-term HRQL after gastrectomy and 
especially, how postoperative BWL may affect HRQL. In this study we assessed 
HRQL in patients surviving at least 2 years after curative gastric cancer resection. It 
was hypothesised that the magnitude of BWL may be related to HRQL impairment. 
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METHODS 
Study population 
Consecutive patients undergoing curative gastric cancer resection were 
recruited between October 2004 and May 2014 at Hospital Universitari del Mar 
(Barcelona, Spain). Total or subtotal gastric resection, depending upon the location 
and the extent of the tumour, with modified D2 lymphadenectomy was undertaken. 
A 70 cm Roux-en-Y loop reconstruction was performed in all cases. In the context 
of clinical trials carried out during the study period, perioperative chemotherapy or 
adjuvant chemoradiation was offered to a subgroup of patients with clinical stage 
II/III disease. Tumour stage was defined according to the system of the International 
Union Against Cancer(18). Postoperative complications were categorised according 
to a modified Clavien-Dindo classification(19). Sepsis was defined as an infection 
that had evoked a systemic inflammatory response syndrome (SIRS)(20). 
Patients who had survived for at least 2 years, and had completed the HRQL 
questionnaires were eligible for the study. Excluded were patients who had 
recurrence, concurrent malignancy, multivisceral resections, cognitive deterioration, 
and those who declined to complete the study questionnaires. The Ethics 
Committee of Hospital Universitari del Mar approved the study and written informed 
consent was obtained from all participants.  
All patients were seen at the outpatient clinic by a medical oncologist and a 
surgeon at 3 months intervals during the first 2 years after surgery; and every 6 
months until they completed 5 years postoperatively. After surgery, patients were 
referred to the Nutrition and Dietetic Outpatient Clinic for nutritional guidance, 
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although no specific strategy for the provision of oral nutritional supplements was 
instituted. 
Assessment of preoperative and postoperative weight 
 Height and weight were measured at the first visit (less than 2 weeks) before 
the operation. Preoperative BWL was calculated using the formula average weight 
(kg) minus weight at time of surgery (kg) / average weight (kg) (14). Body mass 
index (BMI), using the standard formula weight (kg)/height (m2), was calculated at 
baseline and at 6, 12 and 24 months after surgery. The percentage of postoperative 
weight change was calculated using the formula weight at time of surgery (kg) 
minus current weight (kg) / weight at time of surgery (kg) at 6 months, 12 months 
and 2 years postoperatively.  
Health-related quality of life  
 HRQL was assessed with the validated European Organisation for Research 
and Treatment of Cancer (EORTC) core questionnaire, EORTC Quality of Life 
Questionnaire (QLQ-C30) (version 3.0) and the specific module for gastric cancer 
EORTC QLQ-STO22. Permission from EORTC was obtained in order to use them.  
EORTC QLQ-C30 is a 30-item questionnaire composed of multi-item scale and 
single items that reflects the multidimensionality of the quality of life in patients with 
cancer. It incorporates five functional scales (physical, role, cognitive, emotional and 
social), three symptom scales (fatigue, pain and nausea and vomiting) and a global 
health scale. It also includes single items commonly reported by cancer patients 
(10,21). The validated EORTC QLQ-STO22 contains 22 items structured in five 
scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single 
items (22). Patients were asked to complete the questionnaires by themselves at 
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home. If patients showed difficulties to understand questionnaires, additional help 
was provided. Baseline HRQL assessment was performed less than 2 weeks before 
surgery. Subsequent assessments during the follow-up period were carried out at 6, 
12, and 24 months after surgery. When questionnaires were completed or returned, 
they were checked for missing response. If answers were absent, patients were 
asked to respond(9,11). If responses were still missing from more than half of the 
questions within a scale, these questionnaires were excluded from the analyses, 
according to EORTC recommendations(21,23). 
All responses to the EORTC QLQ-C30 and STO-22 questionnaires were linearly 
transformed into scores from 0 to 100 to standardise the raw score. In the functional 
scales, high scores represent better quality of life (better function), whereas high 
scores in symptom scales and items represent worse problems with symptoms(9). 
Data Analyses 
 Baseline characteristics and HRQL scores were analysed in relation to BWL 
< 10% or ≥ 10% at 2 years. Based on previous studies, a cut-off of 10% was chosen 
because this percentage of BWL is considered as a severe nutritional risk marker 
(12–14,16). Mean scores and 95% confidence intervals (CIs) for HRQL were 
calculated preoperatively and at 2 years after surgery. Changes of 10 or more 
points on a 0 to 100 scale were considered clinically relevant(9,24). Statistical 
analyses were performed using t test and X2 test. P < 0.05 was considered 
statistically significant (two-sided). Responses to symptom scales were 
dichotomised based on whether the patients reported minimal or severe symptoms, 
with “not at all” and “a little” categorised as minimal and “quite a bit” or “very much” 
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categorised as severe (25,26).The SPSS software package (SPSS Inc, Chicago, IL, 
USA), version 20.0, was used. 
RESULTS 
Demographics and Cohort Features 
 During the study period, 119 patients undergoing curative gastric cancer 
resection were recruited. Forty-three patients were excluded from the analysis due 
to reasons depicted in Figure 1. Thus, 76 patients remained for the final analysis. Of 
these patients, baseline measurement of HRQL was missing in four patients: one 
underwent emergency gastric resection and the other three patients did not 
complete them. Preoperative clinical and demographic characteristics in both 
groups are shown in Table 1. BWL > 10% at 2 years was detected in 51 patients 
(67%) whereas the rest of patients (25 patients) experienced BWL < 10%. No 
differences were observed between both groups in any variable except for the type 
of gastrectomy and grade ASA.  
HRQL 2 Years after Surgery in relation to weight loss 
 Patients with > 10% BWL at 2 years after surgery had lower scores in all 
items of the functional scales of EORTC QLQ-C30 but in none of them there were 
clinically relevant differences (mean reduction of > 10 points) (Table 2). Of the 
symptoms reported, patients with > 10% BWL at 2 years postoperatively were 
generally more symptomatic than patients without such percentage of BWL. 
Clinically relevant differences were identified with pain, diarrhoea, eating restrictions 
and financial difficulties (Table 2).  Results at 2 years after surgery showed that up 
to one third of patients reported symptoms categorised as severe (“quite a bit” or 
“very much”) with anxiety (Table 3).  Moreover, more than one fifth of these patients 
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also reported severe problems with fatigue (20.4%), pain (21.6%), eating 
restrictions (29.4 %), having dry mouth (25.5%) and body image (23.6 %). In 
addition, 13.7% of patients with BWL ≥ 10% experienced severe diarrhoea and 
severe nausea and vomiting (Table 3). By contrast, none of the patients with BWL < 
10% experienced severe nausea/vomiting, pain or diarrhoea.  
HRQL before Surgery in relation to weight loss 
Most of the baseline functional scores were poorer in patients who subsequently 
experienced more than 10% of BWL compared to those without this extent of BWL 
(Table 2). However, only differences in role and physical function were clinically 
relevant (i.e. > 10 points different). Baseline symptoms scores were higher among 
patients with BWL ≥ 10%. Clinically relevant differences were only observed in 
relation to fatigue, pain and constipation. Results at baseline showed that one third 
of patients with ≥ 10% BWL reported severe symptoms with anxiety (54.2%), fatigue 
(36.9%) and constipation (31.2%). Moreover, more than one fifth of these patients 
also reported severe symptoms with insomnia (25%), dry mouth (25%), appetite 
loss (22.9%) and pain (20.8%). Severe nausea and vomiting, dyspnoea and 
financial difficulties were only reported by patients that experienced ≥ 10% BWL. 
 
DISCUSSION 
This prospective study examined the relation between HRQL and BWL in 
patients surviving 2 years after curative gastric cancer resection. In our study, 67% 
of patients experienced ≥ 10% of BWL at 2 years of surgery. The patients with ≥ 
10% BWL after 2 years usually reported more symptoms compared with those 
patients with less BWL. It is of note that severe symptoms with nausea and 
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vomiting, pain and diarrhoea were only reported in patients with BWL over 10%. 
Preoperative measurement of HRQL allowed us to explore HRQL differences 
between patient groups before surgery. This showed that patients losing at least 
10% of weight at 2 years experienced preoperatively more fatigue, pain, and 
constipation with a significant reduction in role and physical function as compared to 
patients with a lower percentage of BWL. Moreover, severe symptoms were more 
frequently reported in patients who experience more BWL at 2 years after surgery. 
These findings suggest some relation between weight loss and quality of life in long-
term survivors after gastric cancer resection and it make us aware of the need for 
potential early interventions that could minimise this important problem.  
 A number of studies have described the great impact of gastric resection on 
HRQL in patients with curable gastric cancer (6,10). It has been shown that HRQL 
is influenced by the extent of resection (total vs. subtotal or proximal gastrectomy) 
(4,6) and there is a significant impairment of several aspects of HRQL reported by 
patients in the immediate postoperative period(6). Whilst studies show that 
symptoms improve after 6 or 12 months postoperatively, there is also evidence that 
some symptoms such as fatigue, nausea, pain or diarrhoea remain at 2 years after 
surgery as we observed in the present study(6,7). Other authors have investigated 
how baseline HRQL assessment may predict clinical outcomes(9,10). Avery et al. 
(10) reported worse global health, more nausea and vomiting, pain and fatigue at 
baseline assessment among those patients dying within 2 years after gastric cancer 
resection. A difference in the baseline dyspnoea score, measured by HRQL 
questionnaires, was suggested by Djärv et al. (9) as an independent predictive 
factor of death, but in this study  gastric and oesophageal resection cases were 
analysed together. There are a few studies reporting the relation between 
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postoperative malnutrition and HRQL (14,17,27). Although some of them have 
HRQL baseline assessment, none related HRQL to postoperative BWL. Our study 
identifies some baseline HRQL items related to long-term greater BWL. 
Two studies have previously described 7-15% of BWL after gastric cancer 
resection (14,15). Another study has even identified cachexia in half of the patients 
(9). In agreement with these previous studies, our results show that more than half 
of the patients experienced at least 10% of BWL after gastric cancer resection. 
These results highlight the need for more active clinical interventions to counteract 
malnutrition. Starting nutritional counselling and oral nutritional supplementation 
before surgery should be considered, and especially increasing nutritional support 
within 6 months after surgery, when it seems represent the period of greatest weight 
loss according to our data (data not shown). Although nutritional intervention is 
recommended in the management of BWL, there is still lack of evidence to support 
oral nutritional interventions as an individual strategy(28). Furthermore, 
physiotherapy, psychological assessment and other healthcare support might 
facilitate improvement in common symptoms reported by patients after gastric 
cancer resection, such as fatigue, deterioration in emotional function or pain 
control(29).  
In line with our results, previous studies have found a high prevalence of 
diarrhoea after gastric cancer resection ranging from 20% to 30%(6,7,10,11). In the 
present study, severe diarrhoea was more common in the group of patients with 
>10% BWL (13% versus 0%). In a recent systematic study of a prospective 
consecutive series of 45 disease-free patients after esophagectomy or gastrectomy, 
Henegham et al. (16) found that the incidence of malabsorption at 18 to 24 months 
postoperatively was 71% in the gastrectomy group. The proportion of patients with 
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more than 15% weight loss had significantly lower nutritional risk index scores, and 
a higher incidence of malabsorption compared with those who had less than 15% 
weight loss at 24 months. Additionally, of those patients with malabsorption, 44% 
had exocrine pancreatic insufficiency and 38% had evidence of small intestinal 
bacterial overgrowth. Further studies are required to define a well-established 
diagnostic and therapeutic strategy for amelioration of malabsorption, including the 
substitution with pancreatic enzymes and the treatment of bacterial overgrowth, to 
reduce its incidence and potentially minimise BWL and improve HRQL after gastric 
resection. 
Although our data has been collected accurately, with high compliance even 
in the baseline assessment, the current study was not powered to perform a 
multivariate analysis introducing confounders to identify predictive factors for long-
term BWL after curative gastric cancer resection. Moreover, It is a single centre 
study and a multicentre study would provide data that is more generalizable. 
In summary, more than 50% of patients surviving 2 years after curative 
gastric cancer resection experienced ≥ 10% BWL. These patients suffered from 
more disabling symptoms than those with < 10% BWL, with a relevant negative 
effect on HRQL. These findings support the need for routine early nutritional support 
and counselling in gastric cancer patients undergoing curative surgical treatment.  
 
 
 
  
Climent 12 
Acknowledgments 
The authors wish to acknowledge Sergi Mojal, from the Statistics Unit, IMIM 
(Hospital del Mar Medical Research Institute) for expert help in the statistical 
analysis, and Marta Pulido, MD, for editing the manuscript and editorial assistance. 
Blazeby was supported by the MRC ConDuCT-II Hub (Collaboration and innovation 
for Difficult and Complex randomised controlled Trials In Invasive procedures -
 MR/K025643/1). 
 
Authors´ contribution 
M. Climent: Conception and design, collection of data, assessment of the HRQL, 
critical review of results and writing of the first draft, and approval of the final draft. 
M. Munarriz: Conception and design, collection of data, critical review of results and 
approval of the final draft. 
J. Blazeby: Conception and design, critical review of results and approval of the 
final draft. 
D. Dorcaratto: Conception and design, critical review of results and approval of the 
final draft. 
M.J Carrera: Nutritional follow-up of patients, critical review of results and approval 
of the final draft. 
L. Fontane: Nutritional follow-up of patients, critical review of results and approval of 
the final draft. 
  
Climent 13 
L. Grande: Conception and design, critical review of results and writing of the first 
draft, and approval of the final draft. 
M. Pera: Contribution of design and interpretation of results, critical review of results 
and writing of the first draft, and approval of the final draft. 
 
REFERENCES 
1.  Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJH, 
Nicolson M, et al. Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer. New Engl J Med. 2006;355:11–20.  
2.  Noh S, Park S, Yang H, Chung H, Chung I, Kim S, et al. Adjuvant 
capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy 
(CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. 
Lancet Oncol. 2014;12:1389–96.  
3.  Macdonald J, Smalley SR, Benedetti J, Scott AH, Estes NC, Stemmermann 
GN, et al. Chemoradiotherapy after surgery compared with surgery alone for 
adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 
2001;345:725–30.  
4.  Luu C, Arrington AK, Falor A, Kim JAE, Lee B. Impact of gastric cancer 
resection on body mass index. Am Surg. 2014;80:1022–6.  
5.  Gavazzi C, Colatruglio S, Sironi A, Mazzaferro V, Miceli R. Importance of 
early nutritional screening in patients with gastric cancer. Br J Nutr. 
2011;106:1773–8.  
6.  Karanicolas PJ, Graham D, Gönen M, Strong VE, Brennan MF, Coit DG. 
Quality of life after gastrectomy for adenocarcinoma: a prospective cohort 
study. Ann Surg. 2013;257:1039–46.  
7.  Kim AR, Cho J, Hsu Y-J, Choi MG, Noh JH, Sohn TS, et al. Changes of 
quality of life in gastric cancer patients after curative resection. A longitudinal 
cohort study in Korea. Ann Surg. 2012;256:1008–13.  
  
Climent 14 
8.  Kobayashi D, Kodera Y, Fujiwara M, Koike M, Nakayama G, Nakao A. 
Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and 
STO22. World J Surg. 2011;35:357–64.  
9.  Djärv T, Metcalfe C, Avery KNL, Lagergren P, Blazeby JM. Prognostic value 
of changes in health-related quality of life scores during curative treatment for 
esophagogastric cancer. J Clin Oncol. 2010;28:1666–70.  
10.  Avery K, Hughes R, McNair A, Alderson D, Barham P, Blazeby J. Health-
related quality of life and survival in the 2 years after surgery for gastric 
cancer. Eur J Surg Oncol. 2010;36:148–54.  
11.  Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. 
Health-related quality of life among patients with adenocarcinoma of the 
gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J 
Surg. 2008;95:353–61.  
12.  Martin L, Lagergren P. Long-term weight change after oesophageal cancer 
surgery. Br J Surg. 2009;96:1308–14.  
13.  Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T, et 
al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr. 
2006;25:260–74.  
14.  Carey S, Storey D, Biankin A V., Martin D, Young J, Allman-Farinelli M. Long- 
term nutritional status and quality of life following major upper gastrointestinal 
surgery - A cross-sectional study. Clin Nutr. 2011;30:774–9.  
15.  Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer 
patients after total gastrectomy. World J Surg. 1998;22:254–61.  
16.  Heneghan HM, Zaborowski A, Fanning M, McHugh A, Doyle S, Moore J, Ravi 
N RJ. Prospective study of malabsorption and malnutrition after esophageal 
and gastric cancer surgery. Ann Surg. 2015;5:803–7.  
17.  Martin L, Lagergren P. Risk Factors for weight loss among patients surviving 
5 years after esophageal cancer surgery. Ann Surg Oncol. 2014;22:610–6.  
18.  Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant 
tumours. 7th Ed. Wiley-Blackwell. 2009;20–4.  
  
Climent 15 
19.  Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et 
al. The Clavien-Dindo classification of surgical complications: five-year 
experience. Ann Surg. 2009;250:187–96.  
20.  Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference 
on sepsis and organ failure. Chest. 1992;101:1481–3.  
21.  Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D BA. The EORTC 
QLQ-C30 Scoring Manual (3rd edition). Eur Organ Res Treat Cancer. 
2001;1–78.  
22.  Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. 
Clinical and psychometric validation of a questionnaire module, the EORTC 
QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J 
Cancer. 2004;40:2260–8.  
23.  Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. 
The European Organization for Research and Treatment of Cancer QLQ-C30: 
a quality-of-life instrument for use in international clinical trials in oncology. J 
Natl Cancer Inst. 1993;85:365–76.  
24.  Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance 
of changes in health-realted quality-of-life scores. J Clin Oncol. 1998;16:139–
44.  
25.  Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC 
QLQ-C30 quality of life questionnaire in a random sample of the Swedish 
population. Acta Oncol. 2012;51:10–6.  
26.  Djärv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life 
after esophagectomy for cancer. J Clin Oncol. 2009;27:1963–8.  
27.  Marín Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of life 
during cancer. Curr Opin Clin Nutr Metab Care. 2007;10:480–7.  
28.  Baldwin C. The effectiveness of nutritional interventions in malnutrition and 
cachexia. Proc Nutr Soc. 2015;74:397–404.  
29.  Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after 
oesophageal cancer surgery in Sweden. Br J Surg. 2007;94:1496–500.  
  
Climent 16 
 
 
 
 
LEGENDS: 
Figure 1. Flow chart of patients included in the study with number of patients who 
completed the health-related quality of life (HRQL) questionnaires. 
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 Table 1.  Baseline and clinical characteristics of 76 patients who survived at least 2 years after 
curative gastric cancer resection in relation to weight loss ≥ or < 10% at 2 years 
ASA, American Society of Anesthesiologists, BMI: Body mass index. *According to the 7th edition of the International Union 
Against Cancer tumor, node metastasis staging system (18). Results are expressed as number of patients unless otherwise 
stated. 
 
Sex 
    
  Female 31 11 20 0.69 
  Male 45 14 31  
Age, years    
  < 60 16 6 10 0.65 
  ≥ 60 60 19 41  
ASA, grade    
  I - II 43 19 24 0.017 
  III – IV 33 6 27  
Preoperative weight loss     
  < 10 % 62 20 42 0.80 
  ≥ 10  14 5 9  
Preoperative BMI (kg/m²)     
  < 25 24 8 16 0.95 
  ≥ 25 52 17 35  
Preoperative albumin (g/dL)    
  Mean (±SD) 40.1 (±4.5) 40.4 (±4.2) 39.9 (±4.6) 0.67 
pT*     
  Tis /T1 24 11 13 0.35 
  T2 15 4 11  
  T3 26 6 20  
  T4 11 4 7  
pN*    
  N0 42 12 30 0.54 
  N1 16 7 9  
  N2/N3 18 6 12  
pTNM*    
  0 / I  31 12 19 0.44 
  II  29 7 22  
  III  16 6 10  
Type of operation    
  Subtotal gastrectomy 26 14 12 0.005 
  Total gastrectomy  50 11 39  
Neoadjuvant chemotherapy    
  Yes 10 2 8 0.35 
  No 66 23 43  
Adjuvant therapy    
  Yes 16 4 12 0.44 
  No 60 21 39  
Dindo-Clavien grade    
  0 -I 36 12 24 0.93 
  ≥ II 40 13 27  
Sepsis    
  Yes 15 3 12 0.23 
  No 61 22 39  
  
Climent 19 
Table 2. EORTC QLQ-C30 and QLQ-STO-22 scales/items before and 2 years after gastric cancer resection in relation to weight loss ≥ or < 10% at 2 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are expressed as mean (95% CI). Abbreviation: EORTC QLQ, European Organization for Research and treatment of cancer Quality of Life Questionnaire –C30 and STO22; *Higher score 
represent better function; ** Higher score represent more symptoms. MSD: Mean score difference. 
 
  Before Surgery 2 Years After Surgery 
EORTC QLQ  N= 72 N= 76 
C-30 scales/items Weight loss < 10% Weight loss ≥10% 
MSD 
Weight loss < 10% Weight loss ≥10% 
MSD 
 N=24 N=48 N=25 N=51 
Functional scales* 
Global health  74.6 (66 to 83) 65.6 (58 to 72) -9 71.7 (64 to 80) 64.7 (60 to 71) -7 
Physical function 91.4 (86 to 96) 81 (76 to 88) -10.4 87.2 (81 to 94) 79.9 (76 to 87) -7.3 
Role function 93.7 (88 to 99) 77.4 (69 to 89) - 16.3 90 (84 to 96) 82 (78 to 90) -8 
Emotional function 76 (67 to 84) 68.9 (64 to 77) -7.1 76.7 (66 to 87) 74.4 (70 to 83) -2.3 
Cognitive function 84 (77 to 91) 85.4 (80 to 92) 1.4 83.3 (75 to 91) 78.1 (74 to 87) -5.2 
Social function 90.3 (84 to 97) 86.4 (80 to 93) -3.9 91.3 (83 to 99) 85.3 (80 to 93) -6 
Symptom scales/items**     
Fatigue 16.7 (8 to 25) 36.9 (26 to 43) 20 21.8 (12 to 31) 31.1 (24 to 35) 9.3 
Nausea and vomiting 4.2 (0 to 8) 7.9 (2 to 10) 3.7 8 (2 to 14) 16.3 (6 to 20) 8.3 
Pain 9.7 (3 to 16) 26 (16 to 31) 16.3 6 (1 to 11) 23.2 (14 to 29) 17.2 
Dyspnoea 0 7.6 (0 to 14) 7.6 5.3 (0 to 10) 6.5 (2 to 12) 1.2 
Insomnia 22.2 (9 to 36) 29.9 (19 to 39) 7.7 26.7 (12 to 41) 24.2 (14 to 31) -2.5 
Appetite loss 20.8 (8 to 33) 26.4 (14 to 34) 5.6 20 (7 to 32) 20 (10 to 24) - 
Constipation 22.2 (9 to 35) 33.3 (23 to 42) 11.1 14.7 (4 to 25) 8.8 (2 to 15) -5.9 
Diarrhoea 6.9 (-1 to 15) 7.6 (1 to 13) 0.7 10.6 (4 to 17) 20.6 (11 to 27) 10 
Financial difficulties 5.5 (0 to 11) 12.3 (4 to 20) 6.8 6.7 (0 to 13) 18.7 (8 to 26) 12 
EORTC QLQ-STO-22 scales/items**     
Dysphagia  5.5 (0 to 12) 9.9 (4 to 12) 4.4 6.9 (-2 to 16) 14.2 (9 to 18) 7.2 
Pain 12.8 (4 to 23) 20.4 (12 to 26) 7.6 8.7 (1 to 16) 23.1 (15 to 31) 14.4 
Reflux symptoms 11.8 (2 to 24) 9 (6 to 13) 2.8 11.3 (4 to 19) 14.4 (8 to 18) 3.1 
Eating restrictions 8.7 (2 to 16) 16.3 (9 to 22) 7.6 14.4 (8 to 25) 26.1 (18 to 34) 11.7 
Anxiety 44.4 (32 to 52) 45.2 (37 to 51) 0.8 25 (12 to 31) 33.8 (24 to 40) 8.8 
Having dry mouth 25 (11 to 42) 34.7 (23 to 43) 9.7 27.1 (13 to 47) 34 (21 to 41) 6.9 
Taste 6.9 (-2 to 18) 11.8 (3 to 18) 4.9 10.7 (-2 to 18) 18.9 (12 to 34) 8.2 
Body image 13.8 (3 to 30) 15.3 (4 to 21) 1.5 17.3 (5 to 31) 23.5 (4 to 21) 6.2 
Hair loss 6 (-1 to 15) 12.7 (0 to 14) 6.7 13.9 (0 to 23) 6.8 (0 to 14) -7.1 
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Table 3. Percentage of patients reporting “quite a bit” or “very much” with regard to symptoms before and 2 years after gastric cancer resection 
in relation to weight loss ≥  or < 10% at 2 years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are expressed as percentages (95% CIs). Abbreviation: EORTC QLQ, European Organization for Research and treatment of cancer Quality of Life Questionnaire –C30 and STO22; CI 
confidence interval. * Higher scores represent greater proportion of individuals reporting (3) “quite a bit” or (4) “very much” with regard to symptoms (severe symptoms).  
 
Before Surgery 
N= 72 
 
2 Years After Surgery 
N=76 
 
 Weight loss < 10% 
N= 24 
Weight loss ≥10% 
N= 48 
Weight loss < 10% 
N=25 
Weight loss ≥10% 
N= 51 
QLQ-C30       
  Fatigue  12.5 (4 to 31) 36.9 (23 to 49) 20 (9 to 39) 20.4 (11 to 32) 
  Nausea and vomiting  -  10.4 (1 to 22) -  13.7 (7 to 26) 
  Pain 4.1 (1 to 20) 20.8 (12 to 34) -  21.6 (12 to 35) 
  Dyspnoea  -  6.2 (2 to 17) -  2 (1 to 10) 
  Insomnia 16.7 (7 to 36) 25 (15 to 39) 24 (11 to 43) 19.6 ( 11 to 32) 
  Appetite loss 16.7 (7 to 36) 22.9 (13 to 36) 20 (9 to 39) 14 (7 to 26) 
  Constipation  12.5 (4 to 31) 31.2 (20 to 45) 8 (2 to 25) 6.1 (2 to 16) 
  Diarrhoea  8.3 (2 to 26) 6.2 (2 to 17) -  13.7 (7 to 26) 
  Financial difficulty  -  10.9 (4 to 22) 4 (1 to 19) 16 (8 to 28) 
QLQ-STO22         
  Dysphagia  25 (12 to 45) 8.5 (3 to 19) 8 (2 to 25) 11.8 (5 to 23) 
  Pain  17.4 (7 to 36) 18.7 (10 to 32) 4 (1 to 19) 18 (10 to 30) 
  Reflux symptoms  21.7 (9 to 40) 6.2 (2 to 17) 12 (4 to 30) 12 (5 to 23) 
  Eating restrictions 29.1 (15 to 49) 12.5 (6 to 25) 24 (11 to 43) 29.4 (19 to 43) 
  Anxiety 70.8 (51 to 85) 54.2 (40 to 67) 32 (17 to 52) 33 (22 to 47) 
  Having dry mouth  37.5 (21 to 57) 25 (15 to 39) 24 (11 to 43) 25.5 (15 to 39) 
  Taste  20.8 (9 to 40) 4.2 (1 to 14) 12 (4 to 30) 11.8 (5 to 23) 
  Body image  20.8 (9 to 40) 10.4 (4 to 22) 8 (2 to 25) 23.6 (23 to 36) 
  Hair loss  13.6 (4 to 31) 19.1 (10 to 32) 17 (6 to 34) 10 (4 to 20) 
